Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 25-9185-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD185 (CXCR5) Monoclonal Antibody (MU5UBEE), PE-Cyanine7, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The MU5UBEE monoclonal antibody reacts with human and non-human primate CD185. CD185, which is also known as C-X-C chemokine receptor 5 (CXCR5) and Burkitt lymphoma receptor 1 (BLR1), is a seven transmembrane G protein-coupled receptor originally identified in Burkitt's lymphoma. In peripheral blood, CD185 is expressed on B cells, CD4+ T cells (but not Th1 or Th2 cells), as well as on a subpopulation of memory (CD45RO+) T cells. Circulating CD185+ T cells are in a resting state and migrate to the lymph nodes due to expression of CCR7 and CD62L. In tonsil, CD185 is expressed on nearly all CD4+ cells together with CD45RO and activation markers such as CD69 and ICOS. Tonsillar CD185+ cells have been shown to induce antibody production when co-cultured with B cells, thus supporting their role in providing help to B cells. Furthermore, this chemokine receptor plays a critical role in lymphocyte trafficking, in particular T cell migration into the B cell follicles of germinal centers in response to CXCL13, making CD185 an established marker of follicular helper T cells.
- Antibody clone number
- MU5UBEE
- Concentration
- 5 µL/Test
Submitted references Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates.
Obesity and Sex Affect the Immune Responses to Tick-Borne Encephalitis Booster Vaccination.
Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization.
Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes.
Accumulation of follicular CD8+ T cells in pathogenic SIV infection.
Altered immune cell follicular dynamics in HIV infection following influenza vaccination.
Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.
Corbett KS, Gagne M, Wagner DA, Connell SO, Narpala SR, Flebbe DR, Andrew SF, Davis RL, Flynn B, Johnston TS, Stringham C, Lai L, Valentin D, Van Ry A, Flinchbaugh Z, Werner AP, Moliva JI, Sriparna M, O'Dell S, Schmidt SD, Tucker C, Choi A, Koch M, Bock KW, Minai M, Nagata BM, Alvarado GS, Henry AR, Laboune F, Schramm CA, Zhang Y, Wang L, Choe M, Boyoglu-Barnum S, Shi W, Lamb E, Nurmukhambetova ST, Provost SJ, Donaldson MM, Marquez J, Todd JM, Cook A, Dodson A, Pekosz A, Boritz E, Ploquin A, Doria-Rose N, Pessaint L, Andersen H, Foulds KE, Misasi J, Wu K, Carfi A, Nason MC, Mascola J, Moore IN, Edwards DK, Lewis MG, Suthar MS, Roederer M, McDermott A, Douek DC, Sullivan NJ, Graham BS, Seder RA
bioRxiv : the preprint server for biology 2021 Aug 12;
bioRxiv : the preprint server for biology 2021 Aug 12;
Obesity and Sex Affect the Immune Responses to Tick-Borne Encephalitis Booster Vaccination.
Garner-Spitzer E, Poellabauer EM, Wagner A, Guzek A, Zwazl I, Seidl-Friedrich C, Binder CJ, Stiasny K, Kundi M, Wiedermann U
Frontiers in immunology 2020;11:860
Frontiers in immunology 2020;11:860
Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization.
Han Q, Bradley T, Williams WB, Cain DW, Montefiori DC, Saunders KO, Parks RJ, Edwards RW, Ferrari G, Mueller O, Shen X, Wiehe KJ, Reed S, Fox CB, Rountree W, Vandergrift NA, Wang Y, Sutherland LL, Santra S, Moody MA, Permar SR, Tomaras GD, Lewis MG, Van Rompay KKA, Haynes BF
Cell reports 2020 Feb 4;30(5):1553-1569.e6
Cell reports 2020 Feb 4;30(5):1553-1569.e6
Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes.
Jegaskanda S, Mason RD, Andrews SF, Wheatley AK, Zhang R, Reynoso GV, Ambrozak DR, Santos CP, Luke CJ, Matsuoka Y, Brenchley JM, Hickman HD, Talaat KR, Permar SR, Liao HX, Yewdell JW, Koup RA, Roederer M, McDermott AB, Subbarao K
Journal of virology 2018 May 1;92(9)
Journal of virology 2018 May 1;92(9)
Accumulation of follicular CD8+ T cells in pathogenic SIV infection.
Ferrando-Martinez S, Moysi E, Pegu A, Andrews S, Nganou Makamdop K, Ambrozak D, McDermott AB, Palesch D, Paiardini M, Pavlakis GN, Brenchley JM, Douek D, Mascola JR, Petrovas C, Koup RA
The Journal of clinical investigation 2018 May 1;128(5):2089-2103
The Journal of clinical investigation 2018 May 1;128(5):2089-2103
Altered immune cell follicular dynamics in HIV infection following influenza vaccination.
Moysi E, Pallikkuth S, De Armas LR, Gonzalez LE, Ambrozak D, George V, Huddleston D, Pahwa R, Koup RA, Petrovas C, Pahwa S
The Journal of clinical investigation 2018 Jul 2;128(7):3171-3185
The Journal of clinical investigation 2018 Jul 2;128(7):3171-3185
Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.
Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, Carnathan DG, Chandrashekar A, Cirelli KM, Cottrell CA, Eroshkin AM, Guenaga J, Kaushik K, Kulp DW, Liu J, McCoy LE, Oom AL, Ozorowski G, Post KW, Sharma SK, Steichen JM, de Taeye SW, Tokatlian T, Torrents de la Peña A, Butera ST, LaBranche CC, Montefiori DC, Silvestri G, Wilson IA, Irvine DJ, Sanders RW, Schief WR, Ward AB, Wyatt RT, Barouch DH, Crotty S, Burton DR
Immunity 2017 Jun 20;46(6):1073-1088.e6
Immunity 2017 Jun 20;46(6):1073-1088.e6
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with Anti-Human CD19 eFluor® 450 (Product # 48-0199-42) and Mouse IgG2b K Isotype Control PE-Cyanine7 (Product # 25-4732-81) (left) or Anti-Human CD185 (CXCR5) PE-Cyanine7 (right). Cells in the lymphocyte gate were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Extended Immunogen Release Induces Higher nAb Titers Than Conventional Immunization (A-E) Immunogen doses of 100 or 20 mug s.c. immunizations of BG505 SOSIP.664. (A) BG505 nAb titers at week 26 (n = 6 or 12). (B) BG505 SOSIP binding titers at week 26 (n = 6 or 12). (C) Kinetics of BG505 nAb titers. (D and E) GC B cell (D) and GC Tfh cell (E) frequencies after the first, second, and third immunizations. (F-L) Bolus (conventional) versus continuous immunogen delivery of BG505 SOSIP.v5.2 immunogen. (F) Immunization schedule and sampling for continuous antigen delivery using osmotic pumps. (G) BG505 nAb titers in animals immunized by osmotic pump (red) or conventional bolus (Conv, black) ( * p < 0.05; ** p < 0.01; n = 6). (H) Peak BG505 nAb titers after the third immunization (n = 6). (I and J) GC B cell (I) and GC Tfh cell (J) frequencies after the first, second, and third immunizations. (K) Proliferation of GC Tfh cells at week 11. Flow cytometry was gated on CXCR5 hi PD-1 hi GC Tfh cells. (L) Frequency of Ki67 + GC Tfh cells at week 11 (n = 12). All nAb titer and ELISA binding Ab data represent geometric mean titers with geometric SD. All cell-frequency data represent the mean and SD. See also Figure S4 .